Haitham Hamoda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haitham Hamoda has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
Sara Moger
British Menopause Society, UK
6 shared publicationsEdward Morris
Norfolk & Norwich University Hospital, UK
4 shared publications- Hugo Pedder
Bristol Medical School, University of Bristol, Bristol, UK
3 shared publications - Nick Panay
Imperial College London, London, UK
3 shared publications - Abha Maheshwari
School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK
2 shared publications - Amanda J. Vincent
Monash Centre for Health Research and Implementation, Monash University
2 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Taylor & Francis in Climacteric
- p. 1-6
Women’s and health professionals’ needs and preferences informing the updated IMS recommendations
Evidence underpinning recommendations for the health of midlife women (MW), including menopause hormone therapy (MHT), has evolved substantially over the past two decades. The 2016 International Me...
- 24 August 2026
- Published by Taylor & Francis in Climacteric
- p. 1-6
Open AccessWomen’s and health professionals’ needs and preferences informing the updated IMS recommendations
Evidence underpinning recommendations for the health of midlife women (MW), including menopause hormone therapy (MHT), has evolved substantially over the past two decades. The 2016 International Me...
- Top Cited PapersOpen Access
- 2 November 2025
- Published by Taylor & Francis in Climacteric
- Vol. 28 (6) , 634-656
International Menopause Society (IMS) recommendations and key messages on women’s midlife health and menopause
Following a rigorous systematic review of the literature, the International Menopause Society (IMS) has produced detailed new recommendations and key messages on women's midlife health, menopause and menopause hormone therapy (MHT) to help guide healthcare professionals to optimize their management of women at this critical stage of life. The term MHT has been used to cover therapies including estrogens, progestogens and combined regimens. This guidance provides a summary of the recommendations and key messages generated from the systematic review process. The longer version, including the detailed text, key meta-analyses, references, figures and supplementary materials, will be published simultaneously online and can be accessed via the IMS website (https://www.imsociety.org/statements/ims-recommendations/). The quality of evidence and the strength of recommendations used in this guideline are based on the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) and the Appraisal of Guidelines for Research & Evaluation II (AGREE II) approaches. The new recommendations now include levels of evidence, grades of recommendations, good practice points and key messages. The recommendations were developed by a body of 38 authors and 26 support team members derived from the IMS and other organizations. Global stakeholder surveys, targeted at both healthcare providers and consumers, were initially conducted to identify the key questions. A Publication Steering Committee (PSC) provided oversight of the process through regular meetings and ensured consistency of methodology. By the end of the process, 30 completed sections were submitted by the authors to individual lead reviewers selected from the PSC to provide peer review and finally endorsed by the PSC, IMS board and stakeholders. Overall, 341 recommendations (285 supported by research data and 56 good practice points) and 38 key messages have been formulated. These span a diverse range of health topics, including lifestyle, midlife body changes, vasomotor symptoms, genitourinary syndrome of menopause, osteoporosis, cardiometabolic health, dementia, premature ovarian insufficiency and various malignancies. A new section addresses the often-overlooked topic of sarcopenia which requires urgent attention. Current controversial topics, such as the influence of the media, the role of the pharmaceutical industry and publication ethics, are also explored. The overall aim of these recommendations and guidelines is to provide the blueprint for the management of women's midlife health and menopause, given the latest available evidence. In preparing these international recommendations, experts have endeavored to consider geographical variations in medical care, prevalence of diseases/conditions, symptom severity, availability and licensing of MHT and alternatives, and country-specific attitudes of the public, medical community and health authorities toward menopause management.
- 2 November 2025
- Published by Taylor & Francis in Climacteric
- Vol. 28 (6) , 634-656
Top Cited PapersOpen AccessInternational Menopause Society (IMS) recommendations and key messages on women’s midlife health and menopause
Following a rigorous systematic review of the literature, the International Menopause Society (IMS) has produced detailed new recommendations and key messages on women's midlife health, menopause and menopause hormone therapy (MHT) to help guide healthcare professionals to optimize their management of women at this critical stage of life. The term MHT has been used to cover therapies including estrogens, progestogens and combined regimens. This guidance provides a summary of the recommendations and key messages generated from the systematic review process. The longer version, including the detailed text, key meta-analyses, references, figures and supplementary materials, will be published simultaneously online and can be accessed via the IMS website (https://www.imsociety.org/statements/ims-recommendations/). The quality of evidence and the strength of recommendations used in this guideline are based on the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) and the Appraisal of Guidelines for Research & Evaluation II (AGREE II) approaches. The new recommendations now include levels of evidence, grades of recommendations, good practice points and key messages. The recommendations were developed by a body of 38 authors and 26 support team members derived from the IMS and other organizations. Global stakeholder surveys, targeted at both healthcare providers and consumers, were initially conducted to identify the key questions. A Publication Steering Committee (PSC) provided oversight of the process through regular meetings and ensured consistency of methodology. By the end of the process, 30 completed sections were submitted by the authors to individual lead reviewers selected from the PSC to provide peer review and finally endorsed by the PSC, IMS board and stakeholders. Overall, 341 recommendations (285 supported by research data and 56 good practice points) and 38 key messages have been formulated. These span a diverse range of health topics, including lifestyle, midlife body changes, vasomotor symptoms, genitourinary syndrome of menopause, osteoporosis, cardiometabolic health, dementia, premature ovarian insufficiency and various malignancies. A new section addresses the often-overlooked topic of sarcopenia which requires urgent attention. Current controversial topics, such as the influence of the media, the role of the pharmaceutical industry and publication ethics, are also explored. The overall aim of these recommendations and guidelines is to provide the blueprint for the management of women's midlife health and menopause, given the latest available evidence. In preparing these international recommendations, experts have endeavored to consider geographical variations in medical care, prevalence of diseases/conditions, symptom severity, availability and licensing of MHT and alternatives, and country-specific attitudes of the public, medical community and health authorities toward menopause management.
- Open Access
- 22 August 2025
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 31 (4) , 249-253
The use of HRT containing transdermal estradiol in women with a personal history of venous or arterial thromboembolism: A consecutive series of 115 cases
Objective: To assess the risk of further thrombosis with using HRT containing transdermal estradiol in women with a personal history of venous thromboembolism (VTE) or arterial thromboembolism (ATE). Methods: We undertook analysis of patients with a history of VTE/ATE who had been seen in the menopause clinic at King’s College Hospital. They were followed up for a minimum of a 12 months period to assess for recurrence of VTE/ATE. Results: The study included 115 patients with a personal history of VTE/ATE who had used HRT for over a year. 81% had a history of a VTE, 19% had suffered from an ATE. Patients had taken HRT containing transdermal estradiol +/− micronised progesterone or Mirena coil or combined transdermal HRT for a range of 1–20 years, with an average duration of 3 years. 11 patients had switched from oral HRT to transdermal HRT after visiting the clinic. All patients had been referred to a haematologist with 20% of patients requiring life-long anticoagulation based on their medcial background history. 64% of the patients had documented thrombophilia results with 42% of those being positive for a thrombophilia. 39/115 patients required a higher dose of estrogen, taking either more than two pumps of gel/spray or >50 micrograms in the form of a patch. Significantly on follow up (up to 12 months or more), none of the patients had a recurrence of a thromboembolism within 12 months of starting HRT containing transdermal estradiol. Conclusion: To our knowledge, this is the first study assessing the use of HRT containing transdermal estradiol in women with a personal history of VTE/ATE. None of the patients assessed had a thromboembolic event within 12 months of follow up. This study will enable more clinicians to consider prescribing HRT in patients with a personal history of VTE/ATE and higher patient uptake, after individualised risk-assessments.
- 22 August 2025
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 31 (4) , 249-253
Open AccessThe use of HRT containing transdermal estradiol in women with a personal history of venous or arterial thromboembolism: A consecutive series of 115 cases
Objective: To assess the risk of further thrombosis with using HRT containing transdermal estradiol in women with a personal history of venous thromboembolism (VTE) or arterial thromboembolism (ATE). Methods: We undertook analysis of patients with a history of VTE/ATE who had been seen in the menopause clinic at King’s College Hospital. They were followed up for a minimum of a 12 months period to assess for recurrence of VTE/ATE. Results: The study included 115 patients with a personal history of VTE/ATE who had used HRT for over a year. 81% had a history of a VTE, 19% had suffered from an ATE. Patients had taken HRT containing transdermal estradiol +/− micronised progesterone or Mirena coil or combined transdermal HRT for a range of 1–20 years, with an average duration of 3 years. 11 patients had switched from oral HRT to transdermal HRT after visiting the clinic. All patients had been referred to a haematologist with 20% of patients requiring life-long anticoagulation based on their medcial background history. 64% of the patients had documented thrombophilia results with 42% of those being positive for a thrombophilia. 39/115 patients required a higher dose of estrogen, taking either more than two pumps of gel/spray or >50 micrograms in the form of a patch. Significantly on follow up (up to 12 months or more), none of the patients had a recurrence of a thromboembolism within 12 months of starting HRT containing transdermal estradiol. Conclusion: To our knowledge, this is the first study assessing the use of HRT containing transdermal estradiol in women with a personal history of VTE/ATE. None of the patients assessed had a thromboembolic event within 12 months of follow up. This study will enable more clinicians to consider prescribing HRT in patients with a personal history of VTE/ATE and higher patient uptake, after individualised risk-assessments.
- 22 April 2025
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 31 (2) , 73-86
MenoScale: A novel digital tool to measure menopause symptoms and subjective quality of life – validation, preliminary insights on the menopausal experience and association with diet quality
Background: Menopause symptoms significantly impact women’s quality of life, yet existing assessment tools may not fully capture the menopausal experience. The MenoScale is a new digital tool for reporting the number and impact of menopause-associated symptoms. Objective: To evaluate the reliability and validity of the MenoScale, and explore its application as a research tool. Study design: Development of novel MenoScale tool and an online validation study comparing it to the Greene Climacteric Scale (GCS) and RAND 36-item Health Survey 1.0, with 1010 peri- and postmenopausal women aged 37–70 years. Main outcome measures: Construct validity, internal consistency, test-retest reliability, and associations with quality of life and dietary intake. Results: The MenoScale showed good agreement between the MenoScale and GCS through Bland-Altman plot analysis. Internal consistency varied across four symptom domains: vasomotor, sexual, psychological and cognitive, and somatic (Cronbach’s α = 0.5–0.8). Structural equation modelling revealed psychological and cognitive symptoms as central to the menopausal experience. Higher Healthy Eating Index scores were associated with slightly lower MenoScale scores (β = −0.132, p < .001). In the first 12 weeks post-launch, 65,181 women from 140 countries completed the online MenoScale. Conclusion: The MenoScale is a valid and reliable tool for assessing menopause symptoms, offering a comprehensive assessment of the menopausal experience. The association between diet quality and symptom burden warrants further investigation. The rapid uptake of the online MenoScale demonstrates its potential for large-scale data collection and empowering individuals in managing their menopausal experience.
- 22 April 2025
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 31 (2) , 73-86
MenoScale: A novel digital tool to measure menopause symptoms and subjective quality of life – validation, preliminary insights on the menopausal experience and association with diet quality
Background: Menopause symptoms significantly impact women’s quality of life, yet existing assessment tools may not fully capture the menopausal experience. The MenoScale is a new digital tool for reporting the number and impact of menopause-associated symptoms. Objective: To evaluate the reliability and validity of the MenoScale, and explore its application as a research tool. Study design: Development of novel MenoScale tool and an online validation study comparing it to the Greene Climacteric Scale (GCS) and RAND 36-item Health Survey 1.0, with 1010 peri- and postmenopausal women aged 37–70 years. Main outcome measures: Construct validity, internal consistency, test-retest reliability, and associations with quality of life and dietary intake. Results: The MenoScale showed good agreement between the MenoScale and GCS through Bland-Altman plot analysis. Internal consistency varied across four symptom domains: vasomotor, sexual, psychological and cognitive, and somatic (Cronbach’s α = 0.5–0.8). Structural equation modelling revealed psychological and cognitive symptoms as central to the menopausal experience. Higher Healthy Eating Index scores were associated with slightly lower MenoScale scores (β = −0.132, p < .001). In the first 12 weeks post-launch, 65,181 women from 140 countries completed the online MenoScale. Conclusion: The MenoScale is a valid and reliable tool for assessing menopause symptoms, offering a comprehensive assessment of the menopausal experience. The association between diet quality and symptom burden warrants further investigation. The rapid uptake of the online MenoScale demonstrates its potential for large-scale data collection and empowering individuals in managing their menopausal experience.
- 14 May 2024
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 30 (2) , 95-116
Management of unscheduled bleeding on HRT: A joint guideline on behalf of the British Menopause Society, Royal College Obstetricians and Gynaecologists, British Gynaecological Cancer Society, British Society for Gynaecological Endoscopy, Faculty of Sexual and Reproductive Health, Royal College of General Practitioners and Getting it Right First Time
Unscheduled bleeding on hormone replacement therapy (HRT) can affect up to 40% of users. In parallel with the increase in HRT prescribing in the UK, there has been an associated increase in referrals to the urgent suspicion of cancer pathway for unscheduled bleeding. On behalf of the British Menopause Society (BMS) an expert review panel was established, including primary and secondary care clinicians with expertise in the management of menopause, with representatives from key related organisations, including the Royal College of Obstetricians & Gynaecologists, the British Gynaecological Cancer Society, British Society for Gynaecological Endoscopy, Royal College of General Practitioners and Faculty of Sexual and Reproductive Health, and service development partners from NHS England and GIRFT (Getting it Right First Time). For each topic, a focused literature review was completed to develop evidence led recommendations, where available, which were ratified by consensus review within the panel and by guideline groups.
- 14 May 2024
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 30 (2) , 95-116
Management of unscheduled bleeding on HRT: A joint guideline on behalf of the British Menopause Society, Royal College Obstetricians and Gynaecologists, British Gynaecological Cancer Society, British Society for Gynaecological Endoscopy, Faculty of Sexual and Reproductive Health, Royal College of General Practitioners and Getting it Right First Time
Unscheduled bleeding on hormone replacement therapy (HRT) can affect up to 40% of users. In parallel with the increase in HRT prescribing in the UK, there has been an associated increase in referrals to the urgent suspicion of cancer pathway for unscheduled bleeding. On behalf of the British Menopause Society (BMS) an expert review panel was established, including primary and secondary care clinicians with expertise in the management of menopause, with representatives from key related organisations, including the Royal College of Obstetricians & Gynaecologists, the British Gynaecological Cancer Society, British Society for Gynaecological Endoscopy, Royal College of General Practitioners and Faculty of Sexual and Reproductive Health, and service development partners from NHS England and GIRFT (Getting it Right First Time). For each topic, a focused literature review was completed to develop evidence led recommendations, where available, which were ratified by consensus review within the panel and by guideline groups.
- Top Cited Papers
- 27 September 2023
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 38 (1) , 101823
Premature ovarian insufficiency, early menopause, and induced menopause
- 27 September 2023
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 38 (1) , 101823
Top Cited PapersPremature ovarian insufficiency, early menopause, and induced menopause
- Open Access
- 8 May 2023
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 29 (2) , 85-93
An evaluation of menopause service delivery during the COVID-19 pandemic
Objective: To investigate the experience of remote outpatient menopause service delivery by clinicians and patients during the COVID-19 pandemic. Methods: Two surveys explored the experiences of patients and clinicians separately. Patients attending menopause clinics in the UK were directed to an online survey which included questions on demographics and on their experience of their most recent appointment. A clinician survey was shared to members of the British Menopause Society (BMS) via email and was made available on the BMS website. It contained questions on clinic characteristics and clinicians’ experience of delivering remote menopause consultations. Surveys were available for completion between 01/12/2020 and 10/02/2021. Results: Of 180 patients who completed the patient survey, 52% felt remote consultations were the same or better than face-to-face consultations, and 90% of patients felt a choice between remote and face-to-face consultations should be offered. Patients overall were satisfied with many aspects of care, though numerous problems were highlighted with appointment administration. Of 76 clinicians who completed the clinician survey, most found remote patient consultations either no different or a bit worse than face-to face consultations but found that they offered more flexibility. In some cases, significant rescheduling was necessary to accommodate for the clinical needs of the consultation. Conclusion: A ‘one-size-fits-all’ approach to managing the delivery of menopause care is not supported by patients or clinicians. There must be a robust process in place to avoid problems with appointment scheduling and associated communications. Lessons learned from the pandemic can help to provide holistic menopause care.
- 8 May 2023
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 29 (2) , 85-93
Open AccessAn evaluation of menopause service delivery during the COVID-19 pandemic
Objective: To investigate the experience of remote outpatient menopause service delivery by clinicians and patients during the COVID-19 pandemic. Methods: Two surveys explored the experiences of patients and clinicians separately. Patients attending menopause clinics in the UK were directed to an online survey which included questions on demographics and on their experience of their most recent appointment. A clinician survey was shared to members of the British Menopause Society (BMS) via email and was made available on the BMS website. It contained questions on clinic characteristics and clinicians’ experience of delivering remote menopause consultations. Surveys were available for completion between 01/12/2020 and 10/02/2021. Results: Of 180 patients who completed the patient survey, 52% felt remote consultations were the same or better than face-to-face consultations, and 90% of patients felt a choice between remote and face-to-face consultations should be offered. Patients overall were satisfied with many aspects of care, though numerous problems were highlighted with appointment administration. Of 76 clinicians who completed the clinician survey, most found remote patient consultations either no different or a bit worse than face-to face consultations but found that they offered more flexibility. In some cases, significant rescheduling was necessary to accommodate for the clinical needs of the consultation. Conclusion: A ‘one-size-fits-all’ approach to managing the delivery of menopause care is not supported by patients or clinicians. There must be a robust process in place to avoid problems with appointment scheduling and associated communications. Lessons learned from the pandemic can help to provide holistic menopause care.
- 31 January 2023
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 29 (1) , 4-5
Menopause care for women: Supporting the NHS to support women
- 31 January 2023
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 29 (1) , 4-5
Menopause care for women: Supporting the NHS to support women
- 14 November 2022
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 28 (4) , 254-258
Authors reply: ‘Response to the British Menopause society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology position statement – Best practice recommendations for the care of women experiencing the menopause’
- 14 November 2022
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 28 (4) , 254-258
Authors reply: ‘Response to the British Menopause society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology position statement – Best practice recommendations for the care of women experiencing the menopause’